South San Francisco, CA — March 8, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab) plus…Original Article
You may also like
FDA Approves Hympavzi (marstacimab-hncq) for the...
FDA Approves Itovebi (inavolisib) for the Combination...
U.S. Food and Drug Administration Approves...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar...
Dupixent Approved in the US as the First-Ever Biologic...
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.